Page 5 - Kyle Mikson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Exact Sciences (EXAS) Q3 2023 Earnings Call Transcript

EXAS earnings call for the period ending September 30, 2023.

United statesWilliam blairAmerica merrill lynchAndrew brackmann william blairKevin conroyDan brennanMark massaroMegan jonesPuneet souda leerinkPatrick donnelly citiVijay kumar evercoreGoldman sachsMatt sykes goldman sachsErik holznechtJeff elliottDan leonard

EXAS Stock: Why This Large Cathie Wood Holding Could Soon Be Profitable

EXAS Stock: Why This Large Cathie Wood Holding Could Soon Be Profitable
investors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investors.com Daily Mail and Mail on Sunday newspapers.

Kyle miksonCanaccord genuityCathie woodCanaccord miksonExact sciencesExact science

T2 Biosystems, Inc (NASDAQ:TTOO) Q3 2023 Earnings Call Transcript

T2 Biosystems, Inc. (NASDAQ:TTOO) Q3 2023 Earnings Call Transcript October 12, 2023 Operator: Greetings. Welcome to T2 Biosystems Preliminary Third Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note this conference is being recorded. […]

United statesJohn spragueKyle miksonJohn sperzelBen haynorUs department of healthBig company stocks toCandida panelSteven alexandra cohen foundationPublic healthResistance panelLyme panelVanderbilt university medical centerAlliance global partnersHuman servicesBacteria panel

FDA Proposal Casts Cloud Over Startups in Lab-Testing Market

A proposed regulatory shift has injected uncertainty into the laboratory-testing market just as startups are advancing an array of tests to detect diseases sooner and personalize treatments.

United statesJeff shurenGreg yapBrian gormleyCanaccord genuityElisa dwyerKyle miksonRadiological healthDrug administrationAmerican clinical laboratory associationKing spaldingMax lifeChief executive atul sharanValid actVan meterWhatsapp channels

Challenges in China spell trouble for Illumina, 10x and others

China’s recovery from its zero-COVID policy has failed to gain the momentum expected, with many experts predicting a slow or even negative growth rate. A slower economy, combined with a push toward self-reliance, bodes poorly for diagnostics manufacturers in the U.S. who may find themselves not just shut out of the huge market but facing stiffer competition around the globe. Further, policies designed to build a domestic next-generation sequencing industry have created headwinds for San Diego-based Illumina Inc. and others, noted Kyle Mikson and Alex Vukasin of Canaccord Genuity in an in-depth report.

Canaccord genuityKyle miksonAlex vukasinSan illumina incSan diego based illuminaNext generation sequencingSpatial biologySingle cell analysisThermo fisher scientific inc